Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: Result of a randomized pilot study

Cancer

Volumn 113, Issue 1, 2008, Pages 143-149

  Dae, Ho Lee ^a   Han, Ji Youn ^a   Heung, Tae Kim ^a   Sung, Jin Yoon ^a   Hong, Ryull Pyo ^a   Kwan, Ho Cho ^a   Shin, Sang Hoon ^a   Yoo, Heon ^a   Lee, Seung Hoon ^a   Jin, Soo Lee ^a  

^a National Cancer Center   (South Korea)

Author keywords

Brain metastasis; Nonsmall cell lung cancer; Primary chemotherapy; Whole brain radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CORTICOSTEROID; DOCETAXEL; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; BRAIN METASTASIS; BRAIN RADIOGRAPHY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 47149093012     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23526     Document Type: Article

References (26)

1. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865-2872.
2. Wen PY, Black PM, Loeffler JS. Metastatic brain cancer. In: DeVita V, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia: Lippincott, Williams, & Wilkins;2001:2655-2670.
3. Olak J, Ferguson MK. Surgical management of second primary and metastatic lung cancer. In: Pass HI, ed. Lung Cancer: Principles and Practice. Philadelphia: Lippincott-Raven;2000:730-741.
4. Davey P. Brain metastases: treatment options to improve outcomes. CNS Drugs. 2002;16:325-338.
5. Lee JS, Murphy WK, Glisson BS, et al. Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol. 1989;7:916-922.
6. Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol. 1999;10:753-759.
7. Herbst RS, Khuri FR, Lu C, et al. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002;95:340-353.
8. Tsao MN, Lloyd N, Wong R, et al. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev. 2006;3:CD003869.
9. World Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO Offset Pub. No. 48. Geneva: World Health Organization; 1979.
10. National Cancer Institute. Cancer Therapy Evaluation Program, Common Toxicity Criteria. Version 2.0. Bethesda, MD: National Cancer Institute; 1999.
11. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
12. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials - EORTC Study Group on Quality of Life. Eur J Cancer. 1994;30A:635-642.
13. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CT in patients with brain metastases. J Neurooncol. 1999;44:275-281.
14. Lee JS, Umsawasdi T, Dhingra HM, et al. Effect of brain irradiation and chemotherapy on myelosuppression in small-cell lung cancer. J Clin Oncol. 1986;4:1615-1619.
15. [No authors listed]. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
16. Schiller JH, Harrington D, Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-982.
17. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001;357:1478-1484.
18. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
19. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-2103.
20. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
21. Han JY, Lee DH, Kim HY, et al. A phase II study of weekly docetaxel plus capecitabine for patients with advanced non small cell lung carcinoma. Cancer. 2003;98:1918-1924.
22. Han JY, Lee DH, Lee SY, et al. Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced non small cell lung carcinoma. Cancer. 2005;104:2759-2765.
23. Han JY, Lim HS, Lee DH, et al. Randomized phase II study of 2 opposite administration sequences of irinotecan and cisplatin in patients with advanced non small cell lung carcinoma. Cancer. 2006;106:873-880.
24. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330-353.
25. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006;24:3340-3346.
26. Lee DH, Han JY, Lee HG, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res. 2005;11:3032-3037.